Skip to content
Buy This GLP
← Research
Evidence

Do GLP-1 Drugs Help Opioid Use Disorder? What Trials Measure

A small liraglutide pilot reported less craving. Larger semaglutide and tirzepatide studies examine different outcomes alongside established opioid use disorder treatment.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
What each opioid use disorder trial measuresLiraglutide pilotOpioid cravingSemaglutide trialAbstinence from nonprescribed opioidsTirzepatide trialStaying on buprenorphine

GLP-1 drugs are being studied alongside established treatment for opioid use disorder. A small residential pilot reported less craving with liraglutide. The trial of oral semaglutide for alcohol use disorder measured different outcomes in a different condition, so its findings cannot answer whether GLP-1 drugs help with opioid use disorder.[1][2]

What the liraglutide pilot measured

The review of GLP-1 studies on smoking cessation examines a separate condition and different outcomes. A result for nicotine does not establish an effect on opioid use.

Penn State investigators reported preliminary results from a randomized, placebo-controlled study in residential treatment (n = 20). Participants recorded opioid cravings in real time. The investigators reported less craving with liraglutide. That small study cannot establish whether participants are more likely to avoid opioids, stay in treatment, or avoid an overdose over time.[1]

What the larger trials are designed to measure

The tirzepatide protocol plans to enroll about 310 adults who recently started buprenorphine. Its primary outcome is whether participants stay on buprenorphine at six months. A separate semaglutide protocol plans to enroll 200 outpatients on buprenorphine or methadone who continue to use nonprescribed opioids. Its primary outcome is abstinence from illicit or nonprescribed opioids during the study treatment period. Both protocols describe research that adds a GLP-1 drug to established care.[3][4]

What records can tell us about overdose

In a U.S. health-record study of 33,006 people with both type 2 diabetes and opioid use disorder, a semaglutide prescription was associated with fewer recorded opioid overdoses over one year than several other diabetes medications. Researchers matched participants on recorded characteristics, but the study did not randomly assign prescriptions. Unmeasured differences could influence the results.[5]

Frequently asked

Do GLP-1 drugs help opioid use disorder?
A small residential liraglutide pilot reported reduced opioid craving. Evidence has yet to establish GLP-1 drugs as effective treatment for opioid use disorder.
What does the tirzepatide study measure?
The primary outcome is whether participants stay on buprenorphine at six months. Everyone in the trial receives established treatment for opioid use disorder.

Sources

  1. [1] Penn State University (2024). Q&A: Can weight loss drugs help in addiction treatment? Penn State. Source
  2. [2] Schacht JP, et al. (2026). Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial The American Journal of Psychiatry. PMID 42522065
  3. [3] Winhusen TJ, et al. (2026). Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the treatment of opioid use disorder (TAB) trial: study design and rationale Contemporary Clinical Trials. PMID 42600923
  4. [4] Freet CS, Shuler K, Kawasaki S, et al. (2025). Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol Addiction Science & Clinical Practice. Source
  5. [5] Wang W, Wang Q, Davis PB, Volkow ND, Xu R (2024). Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder JAMA Network Open. PMID 39320894
  6. [6] Substance Abuse and Mental Health Services Administration (2025). Treatment Options for Substance Use Disorder SAMHSA. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence